Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 8—August 2005
Dispatch

Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†Comments to Author , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Table A3

Neuraminidase efficacy and related parameters included in the model

Variable Point estimate Range Reference
Efficacy of antiviral prophylaxis*
Preexposure prophylaxis† 71 57–85 24,28
Postexposure prophylaxis† 36 25–47 29
Efficacy of antiviral therapy
% reduction in hospitalization 59 30–70 27
% reduction in antimicrobial drug use 63 40–80 26
Reduction in lost work days under treatment 1 0.5–1.5 26
Annual probability of pandemic (%) 3 1–10 Assumed
% patients seeking medical care within 48 hours 80 70–90 16

*Efficacy presented as percent reduction of attack rate.
†Based on a meta-analysis of 2 studies (see text for details).

Main Article

References
  1. WHO consultation on priority public health interventions before and during an influenza pandemic, Geneva, 16–18 March 2004. Wkly Epidemiol Rec. 2004;79:107–8.PubMedGoogle Scholar
  2. Meltzer  MI, Cox  NJ, Fukuda  K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659–71. DOIPubMedGoogle Scholar
  3. World is ill-prepared for "inevitable" flu pandemic. Bull World Health Organ. 2004;82:317–8.PubMedGoogle Scholar
  4. Cohen  Y. Tamiflu pharmaco-economic dossier, part C: evaluation of influenza cost of illness in Israel. Natanya (Israel): Quintiles Israel; 2000. p. 1–46.
  5. Statistical abstract of Israel 2003, no. 54. Jerusalem: Israel Central Bureau of Statistics; 2003.
  6. Longini  IM Jr, Halloran  ME, Nizam  A, Yang  Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623–33. DOIPubMedGoogle Scholar
  7. McClellan  K, Perry  CM. Oseltamivir: a review of its use in influenza. Drugs. 2001;61:263–83. DOIPubMedGoogle Scholar
  8. Lazzari  S, Stohr  K. Avian influenza and influenza pandemics. Bull World Health Organ. 2004;82:242.PubMedGoogle Scholar
  9. Balicer  RD, Huerta  M, Grotto  I. Tackling the next influenza pandemic. BMJ. 2004;328:1391–2. DOIPubMedGoogle Scholar
  10. Soares  C. Cooping up avian flu. Sci Am. 2005;292:20–2. DOIPubMedGoogle Scholar
  11. Blendon  RJ, Benson  JM, DesRoches  CM, Raleigh  E, Taylor-Clark  K. The public's response to severe acute respiratory syndrome in Toronto and the United States. Clin Infect Dis. 2004;38:925–31. DOIPubMedGoogle Scholar
  12. Finland says it's to buy stocks of Roche's Tamiflu. Reuters Health Information [serial online], Mar 10, 2005 [cited 15 May 2005]. Available from http://www.influenza.com/
  13. Coombes  R. UK stocks up on antiviral drug to tackle flu outbreak. BMJ. 2005;330:495. DOIPubMedGoogle Scholar
  14. Statistical abstract of Israel 2003, no. 54. Jerusalem: Israel Central Bureau of Statistics; 2003.
  15. Meltzer  MI, Cox  NJ, Fukuda  K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659–71. DOIPubMedGoogle Scholar
  16. Cohen  Y. Tamiflu pharmaco-economic dossier, part C: evaluation of influenza cost of illness in Israel. Netanya (Israel): Quintiles Israel; 2000. p. 1–46.
  17. Saito  R, Oshitani  H, Masuda  H, Suzuki  H. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol. 2002;40:84–8. DOIPubMedGoogle Scholar
  18. Hayden  FG, Belshe  RB, Clover  RD, Hay  AJ, Oakes  MG, Soo  W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696–702. DOIPubMedGoogle Scholar
  19. World Health Organization Department of Communicable Disease Surveillance and Response. Avian influenza A(H5N1)—update 22: first data on patients from Viet Nam, clinical data from Hong Kong 1997, susceptibility of H5N1 viruses to antiviral drugs. 2004 Feb 12 [cited 2005 May 25]. Available from http://www.who.int/csr/don/2004_02_12a/en/
  20. Leneva  IA, Roberts  N, Govorkova  EA, Goloubeva  OG, Webster  RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000;48:101–15. DOIPubMedGoogle Scholar
  21. Israeli Ministry of Health. Oseltamivir phosphate. The Israel Drug Registry. 2005 May 24 [cited 2005 May 25]. Available from http://www.health.gov.il/units/pharmacy/trufot/PerutTrufa.asp? Reg_Number=118%2079%2029952%2000&safa=e
  22. Kirkbride  H, Watson  J. A review of the use of neuraminidase inhibitors for prophylaxis of influenza. NI paper for communicable disease and public health (CDPH). UK Health Protection Agency. 2002 Sep 27 [cited 2005 May 25]. Available from http://www.hpa.org.uk/infections/publications/pdf/Neuramindase.pdf
  23. Centers for Disease Control and Prevention. Antiviral agents for influenza: background information for clinicians. 2003 Dec 16 [cited 2005 May 25]. Available from http://www.cdc.gov/flu/professionals/pdf/antiviralsbackground.pdf
  24. Hayden  FG, Atmar  RL, Schilling  M, Johnson  C, Poretz  D, Paar  D, Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336–43. DOIPubMedGoogle Scholar
  25. Treanor  JJ, Hayden  FG, Vrooman  PS, Barbarash  R, Bettis  R, Riff  D, Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016–24. DOIPubMedGoogle Scholar
  26. Cooper  NJ, Sutton  AJ, Abrams  KR, Wailoo  A, Turner  D, Nicholson  KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235–41. DOIPubMedGoogle Scholar
  27. Kaiser  L, Wat  C, Mills  T, Mahoney  P, Ward  P, Hayden  F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–72. DOIPubMedGoogle Scholar
  28. Monto  AS, Robinson  DP, Herlocher  ML, Hinson  JM Jr, Elliott  MJ, Crisp  A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999;282:31–5. DOIPubMedGoogle Scholar
  29. Longini  IM Jr, Halloran  ME, Nizam  A, Yang  Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623–33. DOIPubMedGoogle Scholar
  30. Oxford  JS, Bossuyt  S, Balasingam  S, Mann  A, Novelli  P, Lambkin  R. Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clin Microbiol Infect. 2003;9:1–14. DOIPubMedGoogle Scholar
  31. Breslow  NE. Elementary methods of cohort analysis. Int J Epidemiol. 1984;13:112–5. DOIPubMedGoogle Scholar
  32. Fleiss  JL. The measurement of interrater agreement. In Fleiss JL, editor. Statistical methods for rates and proportions. New York: Wiley; 1981. p. 212–36.
  33. Kleinbaum  DG, Kupper  LL, Morganstern  H. Stratified analysis. In: Epidemiologic research. New York: Van Nostrand Reinhold; 1982. p. 321–76.
  34. Abramson  JH, Gahlinger  PM. Computer programs for epidemiologists: PEPI Version 4.0. Salt Lake City (UT): Sagebrush Press; 2001.
  35. Balicer  RD, Huerta  M, Grotto  I. Tackling the next influenza pandemic. BMJ. 2004;328:1391–2. DOIPubMedGoogle Scholar
  36. Soares  C. Cooping up avian flu. Sci Am. 2005;292:20–2. DOIPubMedGoogle Scholar

Main Article

Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external